Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Company has entered into an initial launch and training agreement for the Delcath Hepatic CHEMOSAT® Delivery system with the Instituto Oncologico Baselga (IOB), Grupo Quiron—a private hospital located in Barcelona, Spain. The CHEMOSAT program at the IOB will be led by Javier Cortes, MD, PhD, Partner and Head of Breast Cancer and Melanoma Programs. Dr. Cortes is also the Head of the Breast Cancer and the Melanoma Programs at Vall d'Hebron University Hospital in Barcelona.
Under the terms of the agreement, the Company will provide the IOB with logistics and clinical training support in the performance of chemosaturation therapy using the CHEMOSAT system. Training is expected to take place in May, and upon completion the site will become the first in Spain to offer Delcath's chemosaturation procedure.
Commenting on the announcement, Dr. Cortes, said, "Instituto Oncologico Baselga is committed to providing state-of-the-art treatment to cancer patients in Spain. The data we have seen suggests Delcath's CHEMOSAT system could be a potentially powerful solution in the treatment of cancers in the liver. We are pleased to be the first institution in Spain to begin exploring the potential of this system in patients with liver tumors originating from a variety of cancers."
"This agreement with IOB represents our first inroads into Spain, one of our core target markets," said Eamonn P. Hobbs, President and CEO of Delcath Systems. "The IOB also represents our fifth center in our fourth European market, following on the centers we have established in France, Germany and Italy. We're pleased with the pace of our rollout of CHEMOSAT in the EU, and expect to announce other new agreements in the coming months."
Innovative urine test could improve pancreatic cancer survival rates